View in EDS

The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.

Saved in:
Bibliographic Details
Title: The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Authors: Gorelik E; Division of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel., Gorelik B, Masarwa R; Division of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel., Perlman A; Division of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel., Hirsh-Raccah B; Division of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel., Matok I; Division of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel. ilan.matok@ekmd.huji.ac.il.
Source: International journal of obesity (2005) [Int J Obes (Lond)] 2020 May; Vol. 44 (5), pp. 1021-1027. Date of Electronic Publication: 2020 Mar 09.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101256108 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5497 (Electronic) Linking ISSN: 03070565 NLM ISO Abbreviation: Int J Obes (Lond) Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5497
DOI:10.1038/s41366-020-0544-4